Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
Noul gets Canadian approval for malaria cartridge as miLab review nears completion
CompaniesNoulAssetsmiLab MAL CartridgeDiseasesmalaria
JW Pharmaceutical files phase 3 IND for biweekly obesity drug bofanglutide
CompaniesJW PharmaceuticalGan & Lee PharmaceuticalsAssetsbofanglutideDiseasesobesity
Retevmo price talks run past deadline, putting September coverage in doubt
CompaniesEli Lilly KoreaNational Health Insurance Service (NHIS)AssetsRetevmo (selpercatinib)Diseaseslocally advanced or metastatic RET fusion-positive non-small cell lung canceradvanced or metastatic RET-mutant medullary thyroid cancer
Lotte Biologics consolidates Korea operations in Songdo ahead of 2027 production
CompaniesLotte Biologics
[Interview] Kidney care shifts to long-term quality of life as treatment outcomes improve
Diseaseskidney transplantationlupus nephritis
Seegene Medical Foundation expands Kazakhstan healthcare ties with diagnostic testing deal
CompaniesSeegene Medical FoundationCentral Asian Biotechnology AssociationOpen Healthcare
SciGen Korea names ex-CSL Behring Korea CEO to lead specialty drug push
CompaniesSciGenCSL BehringEli LillyPfizerAbbVie
Losing 10kg a month on obesity drugs signals high gallstone risk, doctor says
Korean hospital begins offering scalp cooling to reduce breast cancer chemo hair loss
CompaniesDaerim St. Mary's HospitalPaxmanDiseasesbreast cancer
DuChemBio posts record Q2 as diagnostic portfolio expands
CompaniesDuChemBioAssetsNeuraceqVizamyl18F-FP-CITProstaceqFDGDiseasesAlzheimer's diseaseParkinson's diseaseprostate cancer
Celltrion eyes Europe-wide pharmacy sales after integrating France’s Gifrer
CompaniesCelltrionGifrer
Eyes on Asia: Axiom, Pathos AI, Samsung Biologics
CompaniesLEO PharmaTanabe PharmaAssetsdersimelagonDiseaseserythropoietic protoporphyriaX-linked protoporphyria
Neurologic trial failures linked to inadequate measurement tools, study says
FDA committee approves loosening peptide regulation despite own evidence
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play
CompaniesSupernusIndivior
Expedition expedites COPD care with $115m funding boost
CompaniesExpedition TherapeuticsAssetsExpedition's COPD treatmentDiseaseschronic obstructive pulmonary disease
Pharma megamerger speculation collapses: No AstraZeneca-BMS talks
CompaniesAstraZenecaBristol-Myers Squibb
Braveheart prices upsized $382.5m IPO for cardiomyopathy therapeutics
CompaniesBraveheartDiseasescardiomyopathy